PARP1 and endometrial cancer: In the PARP-ICI setting, DOMEC’s lack of benefit in molecularly unselected endometrial cancer contrasts with the activity observed in BRCA-mutated patients and in pMMR tumors harboring HRR alterations in the talazoparib-avelumab trial, pointing towards a convergence of DDR and immune biomarkers [40,41].